bg_biosimilarPOST SUMMARY: Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market.  The biosimilar of Neupogen will save the U.S. health system more than $5.5 billion over the next decade, assuming a “conservative discount of 30 percent off the current brand price,” Express Scripts said